{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:28:33Z","timestamp":1768264113358,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40263-023-01001-y","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T12:02:01Z","timestamp":1684756921000},"page":"453-465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Retrospective Real-Life Multicenter Study on Concurrent Oral Preventive Treatments in Patients with Chronic Migraine Treated with OnabotulinumtoxinA"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2057-7184","authenticated-orcid":false,"given":"Lucas Hendrik","family":"Overeem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4031","authenticated-orcid":false,"given":"Raffaele","family":"Ornello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1874-6611","authenticated-orcid":false,"given":"Maria Magdalena","family":"Pocora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-0725","authenticated-orcid":false,"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0651-1939","authenticated-orcid":false,"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-2113","authenticated-orcid":false,"given":"Cristina","family":"Tassorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aud Nome","family":"Dueland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9758-1494","authenticated-orcid":false,"given":"Bianca","family":"Raffaelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6355-7947","authenticated-orcid":false,"given":"Daniele","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"issue":"19","key":"1001_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M. Migraine. N Engl J Med. 2020;383:1866\u201376.  https:\/\/doi.org\/10.1056\/NEJMra1915327.","journal-title":"N Engl J Med"},{"issue":"13","key":"1001_CR2","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.3390\/jcm10132898","volume":"10","author":"JC Ray","year":"2021","unstructured":"Ray JC, Hutton EJ, Matharu M. OnabotulinumtoxinA in migraine: a review of the literature and factors associated with efficacy. J Clin Med. 2021;10(13):2898.","journal-title":"J Clin Med"},{"issue":"9","key":"1001_CR3","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","volume":"50","author":"A Blumenfeld","year":"2010","unstructured":"Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50(9):1406\u201318.","journal-title":"Headache"},{"issue":"7","key":"1001_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793\u2013803.","journal-title":"Cephalalgia"},{"issue":"7","key":"1001_CR5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804\u201314.","journal-title":"Cephalalgia"},{"issue":"6","key":"1001_CR6","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921\u201336.","journal-title":"Headache"},{"issue":"1","key":"1001_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10194-021-01260-4","volume":"22","author":"K Kollewe","year":"2021","unstructured":"Kollewe K, Gaul C, Gendolla A, Sommer K. Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study. J Headache Pain. 2021;22(1):50.","journal-title":"J Headache Pain"},{"issue":"Suppl 1","key":"1001_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10072-018-3393-3","volume":"39","author":"F Vernieri","year":"2018","unstructured":"Vernieri F, Paolucci M, Altamura C, Pasqualetti P, Mastrangelo V, Pierangeli G, et al. OnabotulinumtoxinA for chronic migraine: a real-life Italian multicenter experience. Neurol Sci. 2018;39(Suppl 1):171\u20132.","journal-title":"Neurol Sci"},{"issue":"7","key":"1001_CR9","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1007\/s10072-020-04283-y","volume":"41","author":"A Santoro","year":"2020","unstructured":"Santoro A, Copetti M, Miscio AM, Leone MA, Fontana A. Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy. Neurol Sci. 2020;41(7):1809\u201320.","journal-title":"Neurol Sci"},{"issue":"4","key":"1001_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/head.13765","volume":"60","author":"A Alpuente","year":"2020","unstructured":"Alpuente A, Gallardo VJ, Torres-Ferr\u00fas M, \u00c1lvarez-Sabin J, Pozo-Rosich P. Short and mid-term predictors of response to onabotulinumtoxinA: real-life experience observational study. Headache. 2020;60(4):677\u201385.","journal-title":"Headache"},{"issue":"5","key":"1001_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00702-016-1539-0","volume":"123","author":"K Kollewe","year":"2016","unstructured":"Kollewe K, Escher CM, Wulff DU, Fathi D, Paracka L, Mohammadi B, et al. Long-term treatment of chronic migraine with onabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting. J Neural Transm (Vienna). 2016;123(5):533\u201340.","journal-title":"J Neural Transm (Vienna)"},{"issue":"5","key":"1001_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1159\/000509853","volume":"83","author":"Y Beckmann","year":"2020","unstructured":"Beckmann Y, \u00c7etin \u00dcnc\u00fc F, Kurt \u0130ncesu T, T\u00fcre S. Effectiveness, safety, and health-related quality of life of chronic migraine patients treated with onabotulinum toxin A. Eur Neurol. 2020;83(5):517\u201322.","journal-title":"Eur Neurol"},{"issue":"1","key":"1001_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s10194-020-01113-6","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Guerzoni S, Baraldi C, Evangelista L, Frattale I, Marini C, et al. Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data. J Headache Pain. 2020;21(1):40.","journal-title":"J Headache Pain"},{"issue":"1","key":"1001_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s10194-016-0702-1","volume":"17","author":"I Aicua-Rapun","year":"2016","unstructured":"Aicua-Rapun I, Mart\u00ednez-Velasco E, Rojo A, Hernando A, Ruiz M, Carreres A, et al. Real-life data in 115 chronic migraine patients treated with onabotulinumtoxin A during more than one year. J Headache Pain. 2016;17(1):112.","journal-title":"J Headache Pain"},{"issue":"1","key":"1001_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1129-2377-15-54","volume":"15","author":"M Khalil","year":"2014","unstructured":"Khalil M, Zafar HW, Quarshie V, Ahmed F. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K. J Headache Pain. 2014;15(1):54.","journal-title":"J Headache Pain"},{"issue":"8","key":"1001_CR16","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/ene.13657","volume":"25","author":"AP Andreou","year":"2018","unstructured":"Andreou AP, Trimboli M, Al-Kaisy A, Murphy M, Palmisani S, Fenech C, et al. Prospective real-world analysis of onabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal. Eur J Neurol. 2018;25(8):1069-e83.","journal-title":"Eur J Neurol"},{"key":"1001_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/bs.pbr.2020.05.013","volume":"255","author":"YF Wang","year":"2020","unstructured":"Wang YF. OnabotulinumtoxinA injection in the treatment of chronic migraine. Prog Brain Res. 2020;255:171\u2013206.","journal-title":"Prog Brain Res"},{"issue":"1","key":"1001_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10194-019-1038-4","volume":"20","author":"EC Agostoni","year":"2019","unstructured":"Agostoni EC, Barbanti P, Calabresi P, Colombo B, Cortelli P, Frediani F, et al. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;20(1):92.","journal-title":"J Headache Pain"},{"issue":"1","key":"1001_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM, et al. European Headache Federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020;21(1):76.","journal-title":"J Headache Pain"},{"issue":"10","key":"1001_CR20","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1111\/ene.14331","volume":"27","author":"A Alpuente","year":"2020","unstructured":"Alpuente A, Gallardo VJ, Torres-Ferr\u00fas M, Santos-Lasaosa S, Guerrero AL, La\u00ednez JM, et al. Evaluation of the concomitant use of oral preventive treatments and onabotulinumtoxinA in chronic migraine: the PREVENBOX study. Eur J Neurol. 2020;27(10):2102\u20138.","journal-title":"Eur J Neurol"},{"issue":"2","key":"1001_CR21","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","volume":"10","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, et al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: a retrospective chart review. Pain Ther. 2021;10(2):809\u201326.","journal-title":"Pain Ther"},{"issue":"9","key":"1001_CR22","doi-asserted-by":"publisher","first-page":"5687","DOI":"10.1007\/s10072-022-06195-5","volume":"43","author":"S Guerzoni","year":"2022","unstructured":"Guerzoni S, Baraldi C, Pani L. The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine. Neurol Sci. 2022;43(9):5687\u201395.","journal-title":"Neurol Sci"},{"issue":"1","key":"1001_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15360288.2020.1829249","volume":"35","author":"M Armanious","year":"2021","unstructured":"Armanious M, Khalil N, Lu Y, Jimenez-Sanders R. Erenumab and onabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis. J Pain Palliat Care Pharmacother. 2021;35(1):1\u20136.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"8","key":"1001_CR24","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1093\/pm\/pnab093","volume":"22","author":"F Cohen","year":"2021","unstructured":"Cohen F, Armand C, Lipton RB, Vollbracht S. Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to onabotulinumtoxinA in patients with chronic migraine. Pain Med. 2021;22(8):1857\u201363.","journal-title":"Pain Med"},{"key":"1001_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.788159","volume":"12","author":"L Mechtler","year":"2021","unstructured":"Mechtler L, Saikali N, McVige J, Hughes O, Traut A, Adams AM. Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to onabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine. Front Neurol. 2021;12: 788159.","journal-title":"Front Neurol"},{"key":"1001_CR26","doi-asserted-by":"publisher","first-page":"656294","DOI":"10.3389\/fneur.2021.656294","volume":"12","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A. Additive interaction between onabotulinumtoxin-A and erenumab in patients with refractory migraine. Front Neurol. 2021;12:656294.","journal-title":"Front Neurol"},{"issue":"7","key":"1001_CR27","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"key":"1001_CR28","doi-asserted-by":"crossref","unstructured":"No authors listed. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"1","key":"1001_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s10194-018-0921-8","volume":"19","author":"L Bendtsen","year":"2018","unstructured":"Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-Rosich P, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018;19(1):91.","journal-title":"J Headache Pain"},{"issue":"1","key":"1001_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/ane.12171","volume":"129","author":"SK Aurora","year":"2014","unstructured":"Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, et al. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand. 2014;129(1):61\u201370.","journal-title":"Acta Neurol Scand"},{"key":"1001_CR31","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3389\/fneur.2019.00678","volume":"10","author":"F Schiano di Cola","year":"2019","unstructured":"Schiano di Cola F, Caratozzolo S, Liberini P, Rao R, Padovani A. Response predictors in chronic migraine: medication overuse and depressive symptoms negatively impact onabotulinumtoxin-A treatment. Front Neurol. 2019;10:678.","journal-title":"Front Neurol"},{"issue":"5","key":"1001_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470\u201385.","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"1001_CR33","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1007\/s10072-012-1059-0","volume":"33","author":"D D'Amico","year":"2012","unstructured":"D\u2019Amico D. Controversies in migraine: monotherapy. Neurol Sci. 2012;33(Suppl 1):S141-5.","journal-title":"Neurol Sci"},{"issue":"Suppl 1","key":"1001_CR34","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1007\/s10072-011-0521-8","volume":"32","author":"D D'Amico","year":"2011","unstructured":"D\u2019Amico D, Curone M, Tullo V, Proietti Cecchini A, Mea E, Bussone G. Polytherapy for the prophylaxis of chronic migraine: an Italian survey. Neurol Sci. 2011;32(Suppl 1):S185-8.","journal-title":"Neurol Sci"},{"issue":"1","key":"1001_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s10194-022-01408-w","volume":"23","author":"R Ornello","year":"2022","unstructured":"Ornello R, Baraldi C, Guerzoni S, Lambru G, Andreou AP, Raffaelli B, et al. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. J Headache Pain. 2022;23(1):38.","journal-title":"J Headache Pain"},{"issue":"1","key":"1001_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","volume":"19","author":"AM Blumenfeld","year":"2018","unstructured":"Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack AA. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13.","journal-title":"J Headache Pain"},{"issue":"Suppl 1","key":"1001_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10072-012-1060-7","volume":"33","author":"G Casucci","year":"2012","unstructured":"Casucci G, Villani V, Cologno D, et al. Polytherapy for migraine prophylaxis. Neurol Sci 2012;33(Suppl 1):147\u2013150. https:\/\/doi.org\/10.1007\/s10072-012-1060-7.","journal-title":"Neurol Sci"},{"issue":"12","key":"1001_CR38","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/14737175.2020.1825077","volume":"20","author":"S Sacco","year":"2020","unstructured":"Sacco S, Russo A, Geppetti P, Grazzi L, Negro A, Tassorelli C, et al. What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. Expert Rev Neurother. 2020;20(12):1275\u201386.","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"1001_CR39","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/head.12781","volume":"56","author":"F Bagnato","year":"2016","unstructured":"Bagnato F, Good J. The use of antiepileptics in migraine prophylaxis. Headache. 2016;56(3):603\u201315.","journal-title":"Headache"},{"issue":"1","key":"1001_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1526-4637.2009.00757.x","volume":"11","author":"AV Krymchantowski","year":"2010","unstructured":"Krymchantowski AV, Jevoux C, Moreira PF. An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine. Pain Med. 2010;11(1):48\u201352.","journal-title":"Pain Med"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01001-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01001-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01001-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T01:21:26Z","timestamp":1685064086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01001-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01001-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"20 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open\nAccess funding enabled and organized by Projekt DEAL. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lucas Hendrik Overeem, Maria Magdalena Pocora, and Daniele Martinelli have no conflicts of interest that are directly relevant to the content of this article. Raffaele Ornello has served on advisory boards for Eli Lilly; received lecture honoraria from Novartis, Eli Lilly, and Teva; received research funding from Novartis and Allergan-AbbVie; and serves on the editorial boards of <i>Frontiers in Pain Research<\/i>, <i>Frontiers in Neurology<\/i>, <i>The Journal of Headache and Pain<\/i>, and <i>Brain Sciences<\/i>. Uwe Reuter has served on advisory boards for Amgen, Allergan, Abbvie, Eli Lilly, Lundbeck, Novartis, and Teva and has received honoraria for lectures from Amgen, Allergan, Abbvie, Eli Lilly, Lundbeck, Novartis, electroCore, Medscape, StreaMedUp, and Teva, received honoraria for consulting services from Lundbeck, Pfizer, and Abbvie; received research funding from Novartis (CHERUB01) and the German Federal Ministry of Education and Research; and is an associate editor of the <i>Journal of Headache and Pain<\/i> and <i>Frontiers in Neurology<\/i>. Simona Sacco has received lecture honoraria from Abbott, Allergan-Abbvie, AstraZeneca, Eli Lilly, Lundbeck, Novartis, NovoNordisk, Pfizer, and Teva, has received research funding from Allergan, Novartis, Uriach, Medscape, and Neurodiem Ology Medical Education, and is Editor-in-Chief of <i>Frontiers in Neurology - Headache and Neurogenic Pain<\/i>, associate editor of the <i>Journal of Headache and Pain<\/i>, Associate Editor of <i>Stroke<\/i>, co-chair of the European Stroke Organization Guidelines Committee, and a board member of the European Headache Federation. Cristina Tassorelli has served on the advisory boards of Abbvie, Domp\u00e9, Eli-Lilly, Lundbeck, Novartis, and Teva; received lecture honoraria from Abbvie, Eli-Lilly, Lundbeck, Novartis, and Teva; honoraria for consulting services from Medscape; received research funding from the EU Commission, the Italian Ministry of Health, the American Migraine Foundation, and Allergan; and serves on the editorial boards of <i>Cephalalgia<\/i> and the <i>Journal of Headache and Pain<\/i>. Aud Nome Dueland served on advisory boards for Lilly, Lundbeck, Novartis, and Teva; received lecture honoraria from Allergan-AbbVie, Lilly, Lundbeck, Novartis, Roche, and Teva; and received honoraria for consulting services from Allergan-AbbVie. Bianca Raffaelli has served on advisory boards for Novartis and Teva; has received lecture honoraria from Allergan, Lilly, Novartis, and Teva; has received research funding from Novartis; and is a member of the editorial boards of the <i>Journal of Headache and Pain<\/i> and <i>Frontiers in Neurology<\/i>.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The study was approved by the ethics committees of the three participating sites under local regulations (Berlin AE1\/159\/22, Pavia 0097925\/21, and L\u2019Aquila 34\/2021).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all patients enrolled in Pavia and L\u2019Aquila centers, while the document was not required in Berlin because of the retrospective nature of the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"LHO had full access to the data in this study and takes responsibility for the data and the accuracy of the data analysis. Study concept and design: RO, AND, BR, DM. Acquisition of data: LHO, RO, MMP, BR, DM. Analysis and interpretation of data: LHO, RO, MMP, BR, DM. Drafting of the manuscript: LHO, RO, MMP, UR, SS, CT BR, DM. Statistical analysis: LHO. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}